Research library

Key finding

In a phase 2 obesity trial, retatrutide reduced mean body weight by up to 24.2% at 48 weeks versus 2.1% with placebo.

Key finding

In the DXA substudy, retatrutide reduced total fat mass by 15.2% to 26.1% at the 4 mg to 12 mg doses over 36 weeks.

Key finding

In a randomized phase 2a analysis, retatrutide produced substantial dose-related reductions in liver fat among participants with metabolic dysfunction-associated steatotic liver disease.

Key finding

In adults with type 2 diabetes, retatrutide produced dose-dependent reductions in HbA1c and body weight over 36 weeks versus placebo and active comparator groups.

Key finding

The discovery programme showed that balanced GIP, GLP-1 and glucagon receptor activity improved glucose control and weight outcomes from animal models through early clinical testing.

Key finding

The study reports that the primary end point was percentage change in weight from baseline to 24 weeks, which ranged from -7.2% to -~18% as the dose of retatrutide increased from 1 mg to 12 mg.

Key finding

Receptor-specific targeting optimizes T2DM treatment, with Semaglutide supporting glycemic control, Tirzepatide enhancing weight loss and glucose regulation, and Retatrutide potentially offering broader metabolic benefits, advancing receptor-targeted, personalized therapy.

Key finding

By recruiting participants with shared disease exposures, the TRIUMPH program will assess the safety and efficacy of retatrutide for the treatment of adults with obesity and two of its common complications-OSA and OA.

Key finding

INTRODUCTION: Despite there being a wide range of medicines available for the treatment of type 2 diabetes, the high rate of mortality suggests treatment needs to be improved.

Key finding

Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.

Key finding

Between Dec 18, 2019, and Dec 28, 2020, 210 people were screened, of whom 72 were enrolled, received at least one dose of study drug, and were included in safety analyses.

Key finding

Retatrutide (both doses) and tirzepatide exhibited superior efficacy compared to other GLP-1 receptor agonists and polyagonists in reducing body weight and waist circumference.

Key finding

Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality.

Key finding

Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.

Key finding

Background This systematic review is registered with CRD42024507397 protocol number and aims to compare the known data about retatrutide on long-term cardiovascular (CV) protection with tirzepatide, an incretin with recent proven CV benefits.

Key finding

The increasing prevalence of obesity and type 2 diabetes mellitus has resulted in a significant challenge to public health throughout the globe.

Key finding

UNLABELLED: Obesity and type 2 diabetes mellitus (T2DM) present major global health challenges, with an increasing prevalence worldwide.

Key finding

Obesity is a chronic condition demanding effective treatment strategies, among which pharmacotherapy plays a critical role.

Key finding

The principle pathological drivers of metabolic dysfunction-associated steatohepatitis (MASH) are obesity and associated insulin resistance, rendering them key therapeutic targets.

Key finding

The study reports that the EBAQ may be used in clinical trials, clinical practice, or observational research to evaluate the impact of obesity and the effect of obesity treatment on appetite and eating behaviors.